Hirofumi Yoshino

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Venues

International journal of molecular sciences

Molecular oncology

FEBS open bio

Cancer science

This page only lists publications with an associated author ORCID identifier.

Publications

Junya Arima, Hirofumi Yoshino, Wataru Fukumoto, Ichiro Kawahara, Saeki Saito, Gang Li, Ikumi Fukuda, Sayaka Iizasa, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita, Masayuki Nakagawa, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer. International journal of molecular sciences 25 (11) (2024)
Ichiro Kawahara, Hirofumi Yoshino, Wataru Fukumoto, Junya Arima, Saeki Saito, Gang Li, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita, Masayuki Nakagawa, Shuichi Tatarano, Yasutoshi Yamada, Enokida Hideki
Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Molecular oncology (2024)
Junya Arima, Hirofumi Yoshino, Wataru Fukumoto, Ichiro Kawahara, Saeki Saito, Gang Li, Ikumi Fukuda, Sayaka Iizasa, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita, Masayuki Nakagawa, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer. International journal of molecular sciences 25 (11) (2024)
Junya Arima, Hirofumi Yoshino, Wataru Fukumoto, Ichiro Kawahara, Saeki Saito, Gang Li, Ikumi Fukuda, Sayaka Iizasa, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita, Masayuki Nakagawa, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer. International journal of molecular sciences 25 (11) (2024)
Hirofumi Yoshino, Seiya Yokoyama, Motoki Tamai, Shunsuke Okamura, Sayaka Iizasa, Takashi Sakaguchi, Yoichi Osako, Satoru Inoguchi, Ryosuke Matsushita, Yasutoshi Yamada, Masayuki Nakagawa, Shuichi Tatarano, Akihide Tanimoto, Enokida Hideki
Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor. FEBS open bio (2023)
Wataru Fukumoto, Hirofumi Yoshino, Shin-Ichi Horike, Issei Kawakami, Motoki Tamai, Junya Arima, Ichiro Kawahara, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Makiko Meguro-Horike, Shuichi Tatarano, Hideki Enokida
Potential therapeutic target secretogranin II might cooperate with hypoxia-inducible factor 1α in sunitinib-resistant renal cell carcinoma. Cancer science (2023)
Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Enokida Hideki, Hirofumi Yoshino
microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1. Molecular oncology 16 (6) (2022)
Shuichi Tatarano, Enokida Hideki, Masaya Yonemori, Rumiko Eura, Hirofumi Yoshino, Hiroaki Nishimura, Yasutoshi Yamada, Masayuki Nakagawa
Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery. Investigative and clinical urology 62 (2) (2022)

Hirofumi Yoshino.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hirofumi Yoshino